<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797589</url>
  </required_header>
  <id_info>
    <org_study_id>2008-001225-34</org_study_id>
    <nct_id>NCT00797589</nct_id>
  </id_info>
  <brief_title>Effect of Prime Solution on Fluid Balance After Open Heart Surgery</brief_title>
  <official_title>Effect of Prime Solution on Fluid Balance After Open Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of Tetraspan速 as prime solution can reduce fluid extravasation after perfusion versus
      Ringer acetate. Plasma-adapted HES-solutions produce also less acidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty patients scheduled for elective primary and single cardiac surgery include in this
      prospective study. Patients with preoperative coagulation disorders, or renal or hepatic
      failure, are excluded.

      Before admission to the operation theatre, the patients allocate in random order to receive
      one of the following solutions during the extracorporeal circulation:

        1. Ringer-acetate solution

        2. 6% HES solution (Tetraspan速) During the 1 postoperative day we register hemodynamic
           changes, fluid balance, fluid extravasation, plasma ion concentration, modified
           thromboelastography, and kidney function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fluid balance</measure>
    <time_frame>1 postoperative day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Valve Surgery</condition>
  <condition>Coronary Artery Bypass Grafting</condition>
  <arm_group>
    <arm_group_label>Ringer lactate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crystalloid solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HES solution (Tetraspan速)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balanced colloid solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HES</intervention_name>
    <description>20ml/kg as prime fluid</description>
    <arm_group_label>HES solution (Tetraspan速)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringer lactate</intervention_name>
    <arm_group_label>Ringer lactate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective combined cardiac surgery

        Exclusion Criteria:

          -  Liver failure

          -  Kidney failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raili T Suojaranta-Ylinen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Alexey Schramko</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>aorta valve</keyword>
  <keyword>mitral valve</keyword>
  <keyword>coronary artery bypass grafting surgery</keyword>
  <keyword>perfusion</keyword>
  <keyword>priming</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

